Sartorius Stedim Biotech S.A. (SDMHF)
OTCMKTS · Delayed Price · Currency is USD
200.95
0.00 (0.00%)
Mar 7, 2025, 3:00 PM EST

Sartorius Stedim Biotech Company Description

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide.

The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products.

It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products.

In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions.

It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories.

The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

Sartorius Stedim Biotech S.A.
Sartorius Stedim Biotech logo
Country France
Founded 1978
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 9,901
CEO Rene Faber

Contact Details

Address:
Zone Industrielle Les Paluds
Aubagne, 13781
France
Phone 33 4 42 84 56 00
Website sartorius.com

Stock Details

Ticker Symbol SDMHF
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency EUR
ISIN Number FR0013154002
SIC Code 3826

Key Executives

Name Position
Dr. Rene Faber Chief Executive Officer and DIrector
Petra Muller Head of Investor Relations
Petra Kirchhoff Head of Corporate Communications and IR